CTOs on the Move


 
Imara Inc. is dedicated to developing novel therapeutics for people living with sickle cell disease and other hemoglobinopathies. Sickle cell disease is a rare, genetic blood disease that causes red blood cells to sickle and become damaged, activating immune cells and blocking blood flow in capillaries, injuring many organs and causing daily pain. Imara is developing IMR-687, a highly selective, potent small molecule inhibitor of phosphodiesterase-9 (PDE9i), to treat patients with sickle cell disease. Imara was launched following an 18-month scientific collaboration between orphan drug accelerator Cydan Development and H. Lundbeck A/S.
  • Number of Employees: 0-25
  • Annual Revenue: $0-1 Million
  • www.imaratx.com
  • 116 Huntington Avenue 6th Floor
    Boston, MA USA 02116
  • Phone: 617.206.2020

Executives

Name Title Contact Details

Funding

Imara raised $63M on 03/18/2019

Similar Companies

Instil Bio

Instil Bio is a cell therapy company developing tumor infiltrating lymphocytes (TIL) for the treatment of solid tumor cancers. TIL are a patient`s own T cells harvested from the patient`s tumor, which are then expanded and reinfused into the patient to target and kill cancer cells.

BioExx Specialty Proteins

BioExx Specialty Proteins Ltd. is a Toronto, ON-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Treasure Coast Radiation Oncology, Pa

Treasure Coast Radiation Oncology, Pa is a Stuart, FL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

480 Biomedical

480 Biomedical focuses on the development of a bioresorbable scaffold for treating occlusive disease in the superficial femoral artery.

ProteoCell Biotechnologies

ProteoCell Biotechnologies Inc. is a Laval, QC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.